dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
Published 4 years ago • 181 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:18
dr. tolba on targeting nrg1 fusions with afatinib
-
2:09
dr. tolba on targeting nrg1 fusions in nsclc
-
2:31
dr. duruisseaux on the incidence of nrg1 fusions in solid tumors
-
12:49
nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
-
5:43
tolerability-guided dose adjustment of afatinib in nsclc
-
2:45
dr. liu on nrg1 fusions in oncology
-
1:14
dr. trombetta on recurrent nrg1 rearrangements in invasive mucinous adenocarcinoma
-
1:25
dr. bunn discusses afatinib in lung cancer
-
1:31
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated adenocarcinoma of the lung
-
3:10
counseling patients with nsclc when kras is detected
-
0:51
dr. tianhong (tina) li reviews the lux-lung 3 trial afatinib data
-
8:03
driver mutations trump pd-l1 expression in lung adenocarcinoma
-
8:11
advances in frontline therapy for egfr nsclc
-
2:03
dr. natale on the utility of pd-l1 and tmb in lung cancer
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
1:21
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated lung cancer in first-line
-
2:45
dr bazhenova on updated data from the trust-i trial of taletrectinib in ros1 nsclc
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc